Guggenheim Reiterates Buy Rating on Relay Therapeutics (RLAY)

August 7, 2026 2:08 AM

Guggenheim analyst Brad Canino reiterated a Buy rating and $26.00 price target on Relay Therapeutics (NASDAQ: RLAY)The analyst comments: “RLAY ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found